Observational studyJournal of neuro-oncology2025
Circulating levels of glutamate predict brain disease in patients with advanced lung and breast cancer: a prospective study.
Observational study in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04785521 (Glutamate Excitotoxicity in Brain Metastases From Lung, Breast and Melanoma Treated With Stereotactic Radiosurgery), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Glutamate Excitotoxicity in Brain Metastases From Lung, Breast and Melanoma Treated With Stereotactic Radiosurgery
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBrain metastases (BM) from lung and breast cancer are a major clinical challenge. Circulating Glutamate (Glut), a key neurotransmitter, may reflect interactions between the tumor and the central nervous system (CNS). The study aims to evaluate its diagnostic value in patients undergoing Gamma Knife Radiosurgery (GKRS) for BMs.
methodsIn this prospective study, pre-treatment serum Glut, Glut-scavengers, and catabolites were quantified in patients with BMs and compared to primary lung/breast cancer patients without BMs and those with benign intracranial tumors. Data were correlated with clinical and radiological features.
resultsThirty-six patients with BMs (lung 75%, breast 25%) were enrolled (median age 66.5 years; median brain tumor volume 4.35 cc). Most patients had extracranial metastases (94.4%) and had received prior systemic therapy (58.3%). During a median follow-up of 7.6 months, 50% of patients experienced disease progression. Peripheral Glut levels were significantly associated with the presence of BMs (p = 0.003), independently of lesion number or brain tumor burden. No correlation was found with other clinical or radiological features. ROC analysis identified a 68.5 µM cut-off for Glut for discriminating between patients with and without BM. In multivariable logistic regression, Glut remained independently associated with BM.
conclusionsCirculating Glut levels are associated with BM presence in advanced lung and breast cancer patients. This measurement is non-invasive and straightforward, and may help identify patients who require brain imaging. Further prospective validation is warranted.
trial registrationThe study was registered in ClinicalTrials.gov with the accession number NCT04785521.
Indexed as
Identifiers
40720079What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.